Pfizer: High Dividend And Low Price Might Still Offset The Expanding Risks
- Pfizer's stock appears undervalued with a high dividend yield of 6.8%, making it a potential long-term investment despite low growth expectations.
- The company reported strong Q3 results with 31.2% YoY revenue growth, driven by products like Paxlovid and Comirnaty.
- Despite high valuation multiples, a DCF analysis suggests Pfizer's intrinsic value is $37.56 with 3% growth, indicating potential undervaluation.
- The health system's potential changes could impact Pfizer, but the low stock price justifies a cautious "Buy" rating.
Massimo Giachetti/iStock Editorial via Getty Images
In my previous and first article about Pfizer Inc. (NYSE:PFE), I argued that the stock could be a bargain. In the meantime, the stock increased a little bit, but especially in the last few days, it declined again and is now trading
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
